Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA. In addition, members of Molecular Partners’ leadership team will participate in upcoming investor events in Switzerland during January 2024.
Conference Presentation Details
Related news for (MOLN)
- Molecular Partners and Orano Med Share Positive DLL3 Preclinical Data
- Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
- Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
- Molecular Partners Publishes Invitation to Annual General Meeting 2023